PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA
Clinical trials for PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough ovarian cancers: testing a powerful drug duo
Disease control Recruiting nowThis study is testing a new combination of two drugs, vismodegib and atezolizumab, for women with ovarian, fallopian tube, or primary peritoneal cancer that has become resistant to platinum-based chemotherapy. The goal is to see if this drug pair can shrink tumors and control the…
Matched conditions: PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: Ronald Buckanovich • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for women with Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis study is testing if a new drug called PLX038 can shrink tumors in people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to standard platinum-based chemotherapy. The drug works by blocking enzymes that cancer cells need to grow…
Matched conditions: PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New hope: using a Patient's own supercharged cells to battle aggressive ovarian cancer
Disease control Recruiting nowThis early-stage study is testing a new personalized treatment for ovarian cancer that has returned or stopped responding to standard therapies. Doctors take a patient's own immune cells, grow and train them in a lab to recognize cancer, and then infuse them back into the patient…
Matched conditions: PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New immune therapy trial offers hope for Tough-to-Treat gynecologic cancers
Disease control Recruiting nowThis study is testing an experimental immunotherapy drug called lorigerlimab for women with advanced ovarian and other gynecologic cancers that have stopped responding to standard platinum-based chemotherapy. About 60 participants will receive the drug through an IV every three w…
Matched conditions: PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Modified virus attacks tough ovarian cancer in new trial
Disease control Recruiting nowThis early-stage trial is testing whether a specially engineered virus called TILT-123, when combined with existing cancer drugs, is safe and potentially effective for women with advanced ovarian cancer that has stopped responding to standard platinum chemotherapy. The virus is d…
Matched conditions: PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC